Edwards Lifesciences Corporation
EW - NYSE - $82.91 ▼ -%0.50
-
Earnings Thu 23 Jul

Edwards opens the
books on Thursday evening.

9 analysts' median target is $95[FMP target], stock is $83, +14.6% upside potential. After Q4 +7.0% EPS beat[FMP earnings], the stock moved +5.6%.

↓ summary below
Quick Take - in 40 seconds
C-
HOLD Council 2/6 - Moonshot 63

C- = MoonshotScore 63[9-pillar formula] + Council 2/6[6-lens rule]. Form 4: 0 transactions[FMP Form 4].

Q4 consensus: revenue $1.7B[FMP est], EPS $0.74[FMP est]. 1 consecutive quarters of beat[FMP earnings].

Detailed analysis below ↓
$0.74 EPS Estimate Last year $0.58 - +10% YoY YoY
1 Beat Streak Expectations beaten consecutively for the last 1 quarters

Q4 EPS +7.0% beat[FMP] but the stock +5.6% D+1[FMP D+1]. Scott Ullem promised $97.4M CapEx + a sequential decline in Q4 during the Q4 earnings call[Scott Ullem capex transcript].

Watchlist

4 metrics stand out this quarter.

2.90 Expectation / Guide

2026 EPS Guidance

2026_EPS_guidance

Edwards Lifesciences indicates an earnings per share (EPS) guidance of $2.90 to $3.05 for 2026.

"We have increased confidence in meeting our 2026 full-year sales growth rate guidance of 8% to 10%, and earnings per share guidance of $2.90 to $3.05."

- Scott Ullem, CFO - Q4 FY25 Earnings Call - February 10, 2026
$2 Investor Focus

TMTT Revenue Target

TMTT_revenue_target

Edwards Lifesciences aims to achieve $2 billion in revenue from the TMTT segment in 2030.

"Together, these are significant advancements for mitral and tricuspid patients and represent large opportunities to achieve our $2 billion revenue expectation for TMTT in 2030."

- Bernard Zovighian, CEO - Q4 FY25 Earnings Call - February 10, 2026
8% Expectation / Guide

2026 Sales Growth Guidance

2026_sales_growth_guidance

Edwards Lifesciences maintains its sales growth guidance of 8% to 10% for 2026.

"Overall, for Edwards Lifesciences Corporation in 2026, we have increased confidence in meeting our 8% to 10% sales growth guidance as well as EPS guidance."

- Bernard Zovighian, CEO - Q4 FY25 Earnings Call - February 10, 2026
2026 Investor Focus

Surgical Product Growth

surgical_product_growth

Edwards Lifesciences expects mid-single-digit sales growth rate in Surgical products in 2026 driven by continued adoption of RESILIA therapies.

"We continue to expect mid-single-digit sales growth rate in Surgical in 2026 driven by continued adoption of our RESILIA therapies that offer extended durability of our surgical therapies."

- Bernard Zovighian, CEO - Q4 FY25 Earnings Call - February 10, 2026

Stock Expert AI - Methodology

Do our 9 pillars, 7 perspectives, and Munger lens point in the same direction?

MoonshotScore 63 / 100

9-pillar methodology. Gross Margin and Cash Runway strong. Operating Leverage weak.

How is it calculated? ->
Revenue Growth4.0Q1 vs Q2: moderate growth (+7.6%)
Gross Margin8.0Q1: very high margin (78.2%, software/cloud territory)
Operating Leverage3.0op margin very strong (31.2%, scale leverage)
Cash Runway10.0FCF very strong ($0.4B, 3.6x CapEx)
R&D Intensity5.0high R&D intensity (17.3%, aggressive)
Price Momentum7.0RSI 53.9 balanced, 50d above
News Sentiment7.0strong buy consensus (73%)
Council Score 2 / 6 Bullish

6 investor frameworks. 2 bullish (Ray Dalio, Ken Griffin), 0 bearish (none), 4 neutral (Jim Simons, Klarman, Buffett, Munger).

How is it calculated? ->
Ray Dalio macro - target upside +14.6%
Ken Griffin flow - 50d MA above
Jim Simons quant - RSI 54
Klarman value - target upside +14.6%
Buffett quality - ROE score 1/5
Munger valuation - target upside +14.6%
Munger's Mindset character & balance sheet lens
Fairly Valued

Quality business, trading at fair value.

How is it calculated? ->
Financial HealthWeak
Margin of SafetyModerate
Interest CoverageAdequate
ROIC vs WACCTight
Technical Levels - Pre-earnings positioning

What levels is the stock being tested at?

RSI(14)
53.9 RSI 53.9 balanced, 50d above
MACD
+0.80 price above 50d - support positive
50d MA
$82 stock 0.8% above - short-term support
200d MA
$81 stock 2.2% above - long-term support
Volume (10d)
-60% decrease - low participation
Resistance
$95
Analyst median target - upgrade trigger if broken
Current
$83
Pre-earnings position
Support
$69
Invalidation - close below this is a technical breakdown
Pattern
Range
$69-$95 band - earnings breakout/breakdown trigger

Past Performance

Edwards's last 8 quarters: 1 consecutive beats.

BEAT
Q2 FY25
$0.67 vs $0.62 est - +5.5%
BEAT
Q3 FY25
$0.67 vs $0.60 est - -1.2%
MISS
Q4 FY25
$0.58 vs $0.62 est - +3.0%
BEAT
Q1 FY26
$0.78 vs $0.73 est - +5.6%

Q4 (February 10, 2026): EPS $0.78 vs $0.73 est[FMP], +7.0% beat. D+1 movement: +5.6%[FMP D+1]. Decline despite beat - market reacted to guidance, not numbers.

Three scenarios: what could happen?

EPS < $0.72 (no guidance)

Q4: EPS $0.78 vs $0.73 beat[FMP], stock +5.6% D+1[FMP].

Backlog concentration

No RPO/backlog concentration disclosed in Q4 earnings call.

CapEx shock

Q4 CapEx $97.4M[FMP cashflow]. Q4 op margin 31.2%[FMP op margin] - this level in Q4 is sensitive to CapEx revision risk.

Framework - Position discipline

After the data arrives: 3 scenarios, 3 windows

Not advice - a structural framework for earnings night. Decision discipline is yours.

Scenario A - Beat
Q4 EPS > $0.74 + CapEx discipline
Threshold: EPS > $0.74[FMP est].
Target: Break above median target $95[FMP target]; high target $110[FMP] upper bound.
Scenario B - In-Line
EPS approx $0.74 + CapEx < $97.4M
Threshold: EPS approx $0.74[FMP est], Q4 CapEx < $97.4M[FMP].
Target: Consolidation in the band between current $83[FMP] and median $95[FMP].
Scenario C - Miss
EPS < $0.72 or CapEx >= $97.4M
Threshold: EPS < $0.72[FMP estx0.97].
Target: Current $83 below SMA200 $81[FMP], if rejection continues, $69[derived] support activates.
Sizing
Earnings volatility -> max portfolio 1-2%. Waiting for earnings is not a gamble, it's a position entrustment.
Timing
IV crush within 24 hours post-earnings. Waiting for premium decay makes options preferable to spot.
Staging
Don't go all-in at once, divide into 3: initial reaction, 24 hours later, after Friday's close.

Market Outlook

What do 9 analysts say?

Wall Street Consensus
$95
12-month median target price (+14.6% upside potential)
22
BUY
8
HOLD
0
SELL
Risk Management
$69
Invalidation level - critical support threshold
$82 - 50-day MA (above, +0.8%)
$81 - 200-day MA (above, +2.2%)
IV Crush risk (sudden drop in inflated option premiums before earnings): Option premiums are inflated before earnings.
Verdict - EW Q4 FY26
C-

You read it in 5 minutes. When the numbers come out on Thursday evening - you know what you're looking at.

Data arrives at night. The framework is ready now.

Data arrives on Thursday evening. The framework is ready on this page: Q4 EPS threshold $0.74[FMP], CapEx threshold "below $97.4M"[Scott Ullem]. Two anchors, three scenarios.

Comparison Stock Expert AI Pro $24/month ($240/year), 77% cheaper than the total of three earnings-tracking tools ($1,059/year -> $240/year).

3 subscriptions. 1 platform.

Seeking Alpha $299/yr - analyst opinions + earnings coverage TipRanks $360/yr - Smart Score (1-10) + analyst consensus + insider trades Trendspider $400/yr - AI pattern detection + automated TA + multi-timeframe alerts

Prices as of April 2026. Sources: seekingalpha.com/subscriptions - tipranks.com/pricing - trendspider.com/pricing

Stock Expert AI Pro: $24/month ($240/year). Council 7-lens analysis + MoonshotScore 9-pillar + Insider tracker + Technical levels - all in one platform, for every stock.

Try Pro free for 14 days EW dossier ->

Educational tool, not investment advice. Past performance does not guarantee future results.

Calendar

Catalyst Calendar - 90-day forward look

Jul 23, 2026EARNINGSQ4 FY26 results (after market close) + earnings call
Jul 24, 2026PRICEFirst trading day after earnings - 200dMA test + IV crush
Sep 6, 2026FILING10-Q deadline - segment breakdown + RPO detail (SEC rule: quarter-end + 45 days)
~Oct 23, 2026EARNINGSQ1 FY27 (next quarter, date not yet scheduled in FMP)

DATA GAP: Events not in the FMP /stable/calendar feed - Investor day, analyst day, product launches, regulatory dates. These require company IR page scraping or manual calendar entry.

Frequently Asked Questions

What does the EW earnings preview cover?

This EW (EW) earnings preview covers the analyst consensus, key catalysts, and what to watch on the earnings call.

What should investors watch for in EW earnings?

Consensus EPS, revenue guidance, segment growth rates, and the tone of management commentary — the full breakdown with sources is on this page.